Bacille Calmette-Guerin (BCG) Vaccine for Immune Protection Against Infections

Overview

This is pilot study of the immunologic effects of intradermal Bacille Calmette-Guerin (BCG) vaccination of adults with cystic fibrosis (CF), non-CF bronchiectasis (NCFB), and healthy volunteers.

Full Title of Study: “Effects of BCG Vaccine on the Immune System of Individuals With Cystic Fibrosis, Non-Cystic Fibrosis Bronchiectasis, and Healthy Volunteers”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: None (Open Label)
  • Study Primary Completion Date: December 30, 2023

Detailed Description

This single-site, open-label clinical trial to investigate the immune effects of BCG vaccination in adults with cystic fibrosis, non-cystic fibrosis bronchiectasis and healthy volunteers by measuring pre and post vaccination immune responses, BCG uptake and protection against infections, including nontuberculous mycobacteria (NTM). This study will also gather data on study feasibility, tolerability, and safety.

Interventions

  • Biological: BCG TICE Vaccine
    • Intradermal vaccination with BCG TICE

Arms, Groups and Cohorts

  • Experimental: Cystic Fibrosis
    • Participants with Cystic Fibrosis.
  • Experimental: Non Cystic Fibrosis Bronchiectasis
    • Participants with Non Cystic Fibrosis Bronchiectasis.
  • Active Comparator: Healthy Volunteer
    • Participants with no condition (healthy volunteers).

Clinical Trial Outcome Measures

Primary Measures

  • BCG Uptake
    • Time Frame: 3 months
    • Change in concentration of IFNgamma levels in blood after BCG incubation relative to baseline.

Participating in This Clinical Trial

Inclusion Criteria (CF and non-CF bronchiectasis):

  • Confirmed diagnosis of either CF or non-CF bronchiectasis – Forced expiratory volume over one second (FEV1) > 40% – Willingness to participate in the study after all aspects of the protocol have been explained and written informed consent obtained. – Available for the study duration, including all planned follow-up visits Inclusion Criteria (Healthy Volunteers): – Negative HIV enzyme-linked immunosorbent assay (ELISA) and confirmatory test at screening. – Willingness to participate in the study after all aspects of the protocol have been explained and written informed obtained. – Available for the study duration, including all planned follow-up visits Exclusion Criteria (All arms): – Current or prior history of active or latent tuberculosis (TB) (per report, not formally tested) or NTM infection – Prior BCG vaccination – Previous vaccine in the past 4 weeks – History of severe anaphylaxis to any vaccine or vaccine components – History of organ/bone marrow transplantation or other immunosuppressing condition, including HIV – Immunosuppressing drugs (including oral corticosteroids equivalent to >10mg of prednisone for 5 days) in the 30 days prior to study enrollment – Cirrhosis or portal hypertension – Pregnant or breastfeeding – Receipt of another investigational product in the last 28 days or planned receipt during this study – Has any other condition that, in the opinion of the principal investigator, would preclude informed consent, make study participation unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving study objectives.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 65 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Johns Hopkins University
  • Collaborator
    • Cystic Fibrosis Foundation
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Noah Lecthzin, MD, MHS, Principal Investigator, Johns Hopkins University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.